ELIQUIS
LEADERSHIP *
* Number 1 prescribed DOAC in Australia † for patients newly diagnosed with DVT , PE or NVAF and ≥1 risk factor for stroke 1 , 2
†
Dispensing data December 2023 , raw unit numbers dispensed from ~ 4000 pharmacies (~ 75-80 % of total retail pharmacy stores ) for total DOAC sales 1
Not a real healthcare professional .
DOAC , direct-acting oral anticoagulant ; DVT , deep vein thrombosis ; NVAF , non-valvular atrial fi brillation ; PE , pulmonary embolism .
PBS Information : Authority required ( STREAMLINED ). Refer to PBS Schedule for full authority information .
PBS codes : NVAF – 4269 and DVT / PE initial treatment – 4098 ( DVT ); 5098 ( PE ). Other PBS codes differ – please refer to PBS Schedule . Before prescribing , please review full Product Information available at www . pfi . sr / eliquispi
ELIQUIS ® ( apixaban ) 2.5 mg and 5 mg tablets . Indications : For use in adult patients for VTE prevention after elective total hip or total knee replacement surgery ; stroke and systemic embolism prevention with non-valvular atrial fi brillation ( NVAF ) with at least one additional factor for stroke ; treatment of deep vein thrombosis ( DVT ) and pulmonary embolism ( PE ); prevention of recurrent DVT and PE . Contraindications : Hypersensitivity to apixaban or tablet excipients ; clinically signifi cant active bleeding ( intracranial , GI ); impairment of haemostasis ; hepatic disease associated with coagulopathy and clinically relevant bleeding risk , severe hepatic impairment ( Child-Pugh C ); severe renal impairment CrCl < 25 mL / min ; organ lesion or conditions at risk of clinically signifi cant major bleeding ; strong inhibitors of both CYP3A4 and P-gp , concomitant anticoagulant treatments . See PI for details . Precautions : Haemorrhage risk : existing conditions with increased bleeding risk ; fall in haemoglobin or blood pressure – search for bleeding site ; discontinue if severe haemorrhage or complications ; consider treatment . Increased risk of thrombotic events after premature discontinuation when transitioning to warfarin ( consider coverage with another anticoagulant ); valvular heart disease ; antiphospholipid syndrome ; active cancer ; acute pulmonary embolism in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy ; patients with provoked VTE ; ischaemic stroke ; renal or hepatic impairment ; elevated liver enzymes or bilirubin ; strong inducers of both CYP3A4 and P-gp ; anticoagulant-related nephropathy ( ARN ); concomitant NSAIDs ; other anti-platelets or antithrombotic agents not recommended ; spinal / epidural anaesthesia or puncture ; indwelling catheters ; neuraxial blockade ; hip fracture surgery ; pregnancy ; lactation ; children ; elderly patients on concomitant acetylsalicylic acid ; effects on clotting tests ; surgery and invasive procedures . See PI for details . Interactions with other Medicines : inducers and inhibitors of both CYP3A4 and P-gp . See PI for details . Adverse Effects : Most common : anaemia , haemorrhage ( including eye , GI , rectal , gingival ), haematoma , haematuria , epistaxis , contusion , nausea , menorrhagia . Others include : thrombocytopenia , hypotension , haemorrhage : intra-abdominal , haemorrhoidal , mouth , vaginal , urogenital , operative , vessel / catheter / incision site , post-procedural bleeding , haematochezia , liver enzymes increased or abnormal , bilirubin increased , wound secretion , haemoptysis , hypersensitivity . Postmarketing ; ARN . See PI for details . Dosage and Administration : VTE prevention in knee / hip replacement surgery : 2.5 mg twice daily . Start 12 to 24 hours after surgery . Take for 32-38 days in hip replacement and 10-14 days for knee replacement . NVAF : 5 mg twice daily ; 2.5 mg twice daily in patients with at least two of the following characteristics : ≥80 yrs ; ≤60 kg ; serum creatinine ≥133 μmol / L . If cardioversion is required , ELIQUIS may be continued or initiated . If not previously treated with anticoagulants ≥5 doses should be taken prior to cardioversion . If < 5 doses taken , a loading dose should be given ( see PI for details ). DVT / PE treatment : 10 mg twice daily for 7 days , followed by 5 mg twice daily . Prevention of recurrent DVT / PE : 2.5 mg twice daily after at least 6 months of treatment for DVT / PE . See PI for details . V10523
References : 1 . NostraData Pty Ltd Hawthorn , Vic . Data on fi le . January 2024 . 2 . Eliquis Approved Product Information .
© 2024 . Bristol Myers Squibb Australia Pty Ltd . ABN 33 004 333 322 . Level 2 , 4 Nexus Court , Mulgrave , Vic 3170 . Pfi zer Australia Pty Ltd . 151 Clarence Street , Sydney , NSW 2000 . ® Registered trademark . PP-ELI-AUS-1266 . ELI-002384-03 . Date of preparation : March 2024 .